ATNM (Actinium Pharmaceuticals) Institutional Ownership: 21.43% (As of Jul. 28, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ATNM Actinium Pharmaceuticals Inc ATNM
11 GF Score
Price $0.85
! 4 Warning Signs
View Full Analysis

What is Actinium Pharmaceuticals Institutional Ownership?

Actinium Pharmaceuticals ATNM 11 Institutional Ownership is 21.43% as of Jul. 28, 2026. GuruFocus rates ATNM with a GF Score™ of 11/100. The stock has 4 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Actinium Pharmaceuticals's institutional ownership is 21.43%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Actinium Pharmaceuticals's Insider Ownership is 1.44%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Actinium Pharmaceuticals's Float Percentage Of Total Shares Outstanding is 99.42%.

Actinium Pharmaceuticals Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Actinium Pharmaceuticals's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Actinium Pharmaceuticals Institutional Ownership Chart

Actinium Pharmaceuticals Historical Data

The historical data trend for Actinium Pharmaceuticals can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 9.53 9.49 9.53 9.20 9.22 9.21 8.42 8.36 8.36 8.32
ATNM
11GF Score
Actinium Pharmaceuticals Inc ATNM
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Actinium Pharmaceuticals Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 21.43% mean?
Actinium Pharmaceuticals (ATNM) has a Institutional Ownership of 21.43% as of Jul. 28, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Actinium Pharmaceuticals and its competitors.
Is Actinium Pharmaceuticals' Institutional Ownership too high?
Actinium Pharmaceuticals' current Institutional Ownership is 21.43%. Overall, Actinium Pharmaceuticals has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Actinium Pharmaceuticals' Institutional Ownership compare to PSTV and IGC?
Actinium Pharmaceuticals' Institutional Ownership of 21.43% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Actinium Pharmaceuticals and its competitors. Actinium Pharmaceuticals's current Institutional Ownership is 21.43%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Actinium Pharmaceuticals stock overvalued right now?
Actinium Pharmaceuticals (ATNM) has a current Institutional Ownership of 21.43%. The current Institutional Ownership is 21.43%. Actinium Pharmaceuticals' overall GF Score™ is 11/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Actinium Pharmaceuticals (ATNM), the current Institutional Ownership is 21.43% as of Jul. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Actinium Pharmaceuticals Business Description

Other Exchanges 7AY1:Germany
Address 100 Park Avenue, 23rd Floor, New York, NY, USA, 10017
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of targeted radiotherapies using its Antibody Radiation Conjugates (ARCs) platform, which combines monoclonal antibodies with radioisotopes to selectively target and destroy cancer cells. The company's product candidates include Iomab-B, an iodine-131 based radiotherapy for conditioning prior to hematopoietic stem cell transplantation, and Actimab-A, an actinium-225 based radiotherapy in clinical development for acute myeloid leukemia. The company is also advancing additional programs, including Iomab-ACT for cell and gene therapy conditioning and other preclinical candidates targeting solid tumors.
11GF Score

Get the complete analysis for ATNM

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.85
Price